Farrow Jeffrey S 4

What Happened

• Jeffrey S. Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals (TARS), had 27,881 restricted stock units (RSUs) vest and convert into shares on June 15, 2026. Following the settlement, 14,396 of those shares were sold in an open-market "sell-to-cover" transaction on June 16, 2026 at $60.95 per share, generating $877,436. The filings show related derivative/settlement disposition entries tied to the RSU conversion.

Key Details

• RSU settlement date: 2026-06-15 (27,881 RSUs settled into shares). (F1, F3, F4)
• Open-market sale: 2026-06-16 — 14,396 shares sold at $60.95 for $877,436. (F2)
• Filing date: 2026-06-17 (filed timely — within 2 business days of the transaction).
• The Form 4 includes a related disposition entry for 27,881 shares at $0 tied to the RSU conversion mechanics (see footnotes).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Footnotes: RSUs granted April 24, 2023 under the 2020 Stock Plan; vesting schedule = 25% each June 15 in 2024–2027. The sale was mandated by the issuer's sell-to-cover tax withholding election and was not a discretionary open-market sale by the reporting person. (F1–F4)

Context

• These transactions reflect a compensation vesting and routine sell-to-cover for tax withholding, not necessarily a signal of the insider’s view on the stock. RSU settlement converted deferred compensation into shares; a portion was sold to satisfy tax obligations per company policy. There is no indication in the filing of a 10b5‑1 plan or a late filing.